Syntara Limited (FRA:UUDA)
Germany · Delayed Price · Currency is EUR | Market Cap | 32.58M +33.2% |
| Revenue (ttm) | 4.25M -8.0% |
| Net Income | -5.45M |
| EPS | -0.00 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0105 |
| Previous Close | 0.0095 |
| Day's Range | 0.0105 - 0.0105 |
| 52-Week Range | 0.0075 - 0.0290 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Syntara
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and is in Phase 1c/2 studies for patients with myelodysplastic syndrome. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a P... [Read more]
Financial Performance
In fiscal year 2025, Syntara's revenue was 7.30 million, an increase of 26.61% compared to the previous year's 5.76 million. Losses were -7.92 million, -47.70% less than in 2024.
Financial numbers in AUD Financial StatementsNews
Syntara Earnings Call Transcript: Q4 2026
Positive FDA feedback and an AUD 8 million capital raise have extended the cash runway through FY 2028, supporting key clinical milestones. Multiple programs are advancing, with pivotal trial starts and major data readouts expected by year-end.
Syntara Earnings release: Q4 2026
Syntara released its Q4 2026 earnings on July 27, 2026, summarizing the period's financial results.
Syntara Slides: Q4 2026
Syntara has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on July 27, 2026.
Syntara Transcript: EGM 2026
Shareholders considered and voted on two resolutions regarding share placements from April 2026, with no questions raised. Voting was conducted by poll, and results will be released to the stock exchange later today.
Syntara Transcript: Status update
SNT-4728, a dual SSAO/MAO-B inhibitor, is in a phase II trial targeting neuroinflammation in prodromal Parkinson's patients with iRBD. The study's primary endpoint is PET-measured neuroinflammation reduction, with results expected by end of June. Safety, strong preclinical evidence, and a clear unmet need support further development.
Syntara Slides: Status update
Syntara has posted slides in relation to its latest quarterly earnings report, which was published on May 31, 2026.
Syntara Transcript: Investor update
Formal FDA alignment on the phase II-B trial for imsulostat de-risks the clinical path and enhances partnering prospects. A recent AUD 8 million capital raise extends the cash runway to Q3 2027, funding multiple clinical milestones and supporting ongoing licensing discussions.
Syntara Slides: Investor update
Syntara has posted slides in relation to its latest quarterly earnings report, which was published on April 29, 2026.
Syntara Press release: Investor update
Syntara issued a press release on April 29, 2026, disclosing material business information to investors.
Syntara Earnings release: Q3 2026
Syntara released its Q3 2026 earnings on April 29, 2026, summarizing the period's financial results.
Syntara Slides: Investor presentation
Syntara has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.
Syntara Transcript: NWR Virtual Healthcare Conference
Syntara highlighted its diversified late-stage pipeline, with multiple clinical readouts expected in the next 12 months. Lead asset amsulostat showed strong efficacy and safety in myelofibrosis, while skin scarring and Parkinson’s programs are advancing with significant commercial interest.
Syntara Quarterly report: H1 2026
Syntara has published its H1 2026 quarterly earnings report on February 24, 2026.
Syntara Slides: Investor presentation
Syntara has posted slides in relation to its latest quarterly earnings report, which was published on February 4, 2026.
Syntara Transcript: Investor update
Entering 2026 with a strong cash position and five clinical trials, the pipeline is set for multiple data readouts, with amsulostat leading in myelofibrosis and MDS. Flexible partnering options and non-dilutive funding support broad optionality and capital efficiency.
Syntara Slides: Investor update
Syntara has posted slides in relation to its latest quarterly earnings report, which was published on February 2, 2026.
Syntara Earnings release: Q2 2026
Syntara released its Q2 2026 earnings on January 28, 2026, summarizing the period's financial results.
Syntara Transcript: Study Update
Scarring remains a major unmet need with no approved therapies that remodel tissue at the biological level. SNT-9465, a next-generation pan-LOX inhibitor, showed promising safety and mechanistic results in early studies and is now in a rigorously designed phase 1b trial for hypertrophic sternotomy scars.
Syntara Transcript: AGM 2025
The meeting highlighted strong clinical progress, robust financial health, and a diversified pipeline with key data readouts expected in the next year. Voting was completed on all resolutions except one withdrawn item, and the company remains well positioned for future growth.
Syntara Slides: FY 2025
Syntara has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 19, 2025.
Syntara Transcript: Bell Potter Healthcare Conference 2025
The conference showcased Syntara's progress with its diverse clinical pipeline, highlighting strong efficacy and safety data for its lead asset in myelofibrosis, upcoming regulatory milestones, and multiple catalysts expected in 2025. Immutep was also introduced, with its lead immunotherapy in a global phase 3 lung cancer trial.
Syntara Earnings release: Q1 2026
Syntara released its Q1 2026 earnings on October 27, 2025, summarizing the period's financial results.
Syntara Slides: Investor Presentation
Syntara has posted slides in relation to its latest quarterly earnings report, which was published on October 13, 2025.
Syntara Transcript: Study Update
Final phase 2A data for amsulastat in myelofibrosis showed 73% of patients achieved significant symptom reduction, with strong spleen volume responses and favorable tolerability. Six of seven completers chose to continue therapy. Regulatory and partnership steps are planned for 2024.
Syntara Press release: Study Update
Syntara issued a press release on September 29, 2025, disclosing material business information to investors.